Your browser doesn't support javascript.
loading
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller, R E; Leary, A; Scott, C L; Serra, V; Lord, C J; Bowtell, D; Chang, D K; Garsed, D W; Jonkers, J; Ledermann, J A; Nik-Zainal, S; Ray-Coquard, I; Shah, S P; Matias-Guiu, X; Swisher, E M; Yates, L R.
Afiliação
  • Miller RE; Department of Medical Oncology, University College London, London, UK; Department of Medical Oncology, St Bartholomew's Hospital, London, UK.
  • Leary A; Department of Medicine and INSERM U981, Gustave Roussy Cancer Center, Université Paris-Saclay, Paris, France.
  • Scott CL; Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.
  • Serra V; Experimental Therapeutics Group Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lord CJ; The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.
  • Bowtell D; Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.
  • Chang DK; Glasgow Precision Oncology Laboratory, Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
  • Garsed DW; Peter MacCallum Cancer Centre, Melbourne, Australia; The University of Melbourne, Melbourne, Australia.
  • Jonkers J; Division of Molecular Pathology, Oncode Institute, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ledermann JA; UCL Cancer Institute, University College London, London, UK.
  • Nik-Zainal S; Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, UK; MRC Cancer Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
  • Ray-Coquard I; Centre Leon Berard, Lyon, France; University Claude Bernard Groupe University of Lyon, France.
  • Shah SP; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Matias-Guiu X; Departments of Pathology, Hospital U Arnau de Vilanova and Hospital U de Bellvitge, Universities of Lleida and Barcelona, Irblleida, Idibell, Ciberonc, Barcelona, Spain.
  • Swisher EM; Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.
  • Yates LR; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge; Guy's Cancer Centre, Guys and St Thomas' NHS Foundation Trust, London, UK. Electronic address: education@esmo.org.
Ann Oncol ; 31(12): 1606-1622, 2020 12.
Article em En | MEDLINE | ID: mdl-33004253
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido